Abstract:Chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies has made great progress, but there are still some problems. First, T cells from tumor patients show an exhaustion phenotype; thus, the persistence and function of the CAR-Ts are poor, and achieving a satisfactory curative effect is difficult. Second, some patients initially respond well but quickly develop antigen-negative tumor recurrence. Thirdly, CAR-T treatment is not effective in some patients and is accompanied by severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity. The solution to these problems is to reduce the toxicity and enhance the efficacy of CAR-T therapy. In this paper, we describe various strategies for reducing the toxicity and enhancing the efficacy of CAR-T therapy in hematological malignancies. In the first section, strategies for modifying CAR-Ts using gene-editing technologies or combining them with other anti-tumor drugs to enhance the efficacy of CAR-T therapy are introduced. The second section describes some methods in which the design and construction of CAR-Ts differ from the conventional process. The aim of these methods is to enhance the anti-tumor activity of CAR-Ts and prevent tumor recurrence. The third section describes modifying the CAR structure or installing safety switches to radically reduce CAR-T toxicity or regulating inflammatory cytokines to control the symptoms of CAR-T-associated toxicity. Together, the knowledge summarized herein will aid in designing better-suited and safer CAR-T treatment strategies.

Research status on immunogenicity of chimeric antigen receptor T cell immunotherapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

[Advances in Structural Designs of Chimeric Antigen Receptor T Cells--Review].

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects.

Current Status and Problems of Chimeric Antigen Receptor T Cell Immunotherapy in Treatment of Hematological Malignancies

[The impact of immune cells selection on the therapeutic efficacy of CAR-T cell therapy]

CAR trafficking does matter: prospects of ‘Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy’

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review

Research Progress on Chimeric Antigen Receptor T Cells——Review

CAR-T Cells for Cancer Immunotherapy—the Barriers Ahead and the Paths Through

Research progress of CAR-T in the treatment of hepatocellular carcinoma

New strategies of tumor therapy by using chimeric antigen receptor-modified immunocyte

Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases